In Segment C, members will receive ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or even the individuals are not able to tolerate the study drugs. For all circulation cytometry experiments, 10,000 cells for every replicate were https://abbv-744therapeuticpotent57902.creacionblog.com/31902216/5-essential-elements-for-abbv-744-drug-development-progress-and-timeline